# Bausch Health Companies Inc. (BHC)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $1.95B  
**Price:** $5.20 (+0.87%)

> Bausch Health Companies Inc. is a diversified healthcare company focused on developing, manufacturing, and marketing branded and generic pharmaceuticals, over-the-counter products, and medical devices. Its portfolio spans gastroenterology, neurology, dermatology, and eye health, with a notable legacy from the acquisition of Bausch + Lomb that established a strong footprint in vision care and ophthalmic pharmaceuticals. Operating within the specialty and generic drug segment, the company emphasizes treatments for chronic conditions and niche therapeutic areas where physician-led adoption and patient adherence are critical. Bausch Health serves patients, healthcare professionals, and institutional buyers across global markets through a mix of prescription brands, generics, and consumer health offerings. The firm’s scale—supported by a large employee base—enables integrated R&D, manufacturing, and distribution, positioning it as a meaningful player in cost-sensitive and specialty therapeutics. Financially, it exhibits characteristics of a value-oriented healthcare issuer, reflecting low price-to-sales and active capital allocation underpinned by ongoing operating profitability metrics.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $10.27B | — | $1.81B | $157M | — |
| 2024 | $9.63B | — | $1.55B | -$46M | — |
| 2023 | $8.76B | — | $963M | -$592M | — |
| 2022 | $8.12B | — | $454M | -$225M | — |
| 2021 | $8.43B | — | $450M | -$948M | — |
| 2020 | $8.03B | — | $676M | -$560M | — |
| 2019 | $8.60B | — | -$203M | -$1.79B | — |
| 2018 | $8.38B | — | -$2.38B | — | — |
| 2017 | $8.72B | $6.22B | $102M | — | — |
| 2016 | $9.67B | $7.10B | -$566M | — | — |
| 2015 | $10.45B | $7.92B | $1.53B | — | — |
| 2014 | $8.21B | $6.03B | $2.00B | — | — |
| 2013 | $5.77B | $3.92B | -$410M | — | — |
| 2012 | $3.48B | $2.58B | $80M | — | — |
| 2011 | $2.43B | $1.74B | $300M | — | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $26.37B | $25.99B | -$554M | $1.31B | $20.82B |
| 2024 | $26.52B | $26.84B | -$1.28B | $1.18B | $21.62B |
| 2023 | $27.35B | $27.43B | -$1.02B | $947M | $22.39B |
| 2022 | $25.69B | $25.43B | -$692M | $564M | $20.77B |
| 2021 | $29.20B | $29.24B | -$106M | $582M | $22.65B |
| 2020 | $31.20B | $30.59B | $535M | $605M | $23.93B |
| 2019 | $33.86B | $32.73B | $1.06B | $3.24B | $25.89B |
| 2018 | $32.49B | $29.68B | $2.73B | $721M | $24.30B |
| 2017 | $37.50B | $31.55B | $5.85B | $720M | $25.44B |
| 2016 | $43.53B | $40.27B | $3.15B | $542M | $29.85B |
| 2015 | $48.97B | $42.94B | $5.91B | $597M | $31.09B |
| 2014 | $26.30B | $20.90B | $5.28B | $323M | $15.23B |
| 2013 | $27.93B | $22.74B | $5.12B | $600M | $17.37B |
| 2012 | $17.95B | $14.23B | $3.72B | $916M | $11.02B |
| 2011 | $13.11B | $9.18B | $3.93B | $164M | $6.65B |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $1.40B | $397M | $1.00B |
| 2024 | $1.60B | $337M | $1.26B |
| 2023 | $1.03B | $215M | $817M |
| 2022 | -$728M | $218M | -$946M |
| 2021 | $1.43B | $269M | $1.16B |
| 2020 | $1.11B | $302M | $809M |
| 2019 | $1.50B | $270M | $1.23B |
| 2018 | $1.50B | $157M | $1.34B |
| 2017 | $2.29B | $171M | $2.12B |
| 2016 | $2.09B | $235M | $1.85B |
| 2015 | $2.26B | $235M | $2.02B |
| 2014 | $2.31B | $292M | $2.02B |
| 2013 | $1.04B | $115M | $927M |
| 2012 | $657M | $108M | $549M |
| 2010 | $263M | $17M | $246M |

Source: [CompaniesByCap](https://companiesbycap.com/company/BHC)